To examine whether miR‐3934‐5p could alter the prostate cancer cell activity by targeting EGFR, gefitinib, an EGFR inhibitor, was added to PC3 NEG and KO cells with DMSO as negative control. This evidence concerns the gene EGFR and prostate carcinoma.